Article Text

This article has a correction. Please see:

Download PDFPDF
Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings
  1. Jose M Rubio1,
  2. Christoph U Corell1,2,3
  1. 1Department of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York, USA;
  2. 2Hofstra Northwell School of Medicine, Hempstead, New York, USA;
  3. 3The Feinstein Institute for Medical Research, Manhasset, New York, USA
  1. Correspondence to Professor Christoph U Corell, Department of Psychiatry, The Zucker Hillside Hospital, 75-59 263rd Street, Glen Oaks, NY 11004, USA; ccorrell{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


What is already known on this topic

Individuals with schizophrenia die ∼15–20 years prematurely compared to the general population, mostly due to cardiovascular disease, obesity-related cancer, diabetes and chronic obstructive pulmonary disease.1 Owing to the known metabolic effects of antipsychotics,2 clarifying their role in increased mortality is important. Paradoxically, prior studies in schizophrenia have suggested a relative decrement in mortality with moderate antipsychotic doses compared to no antipsychotic exposure. Cohort studies have indicated an elevated mortality risk with benzodiazepines in several populations, but adjustment for other treatment variables has been limited.

Methods of the study

A cohort of 21 492 individuals aged 17–65 years old who lived in Sweden in 2005 and who received treatment for schizophrenia prior to the beginning of 2006 was followed for 5 years. This cohort was derived from nationwide registers representing all contacts with healthcare in Sweden during the study period. The cumulative prescription of antipsychotics, benzodiazepines and …

View Full Text


  • Competing interests CUC has been a consultant and/or advisor to or has received honoraria from Alkermes, Forum, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, Lundbeck, Medavante, Medscape, Otsuka, Pfizer, ProPhase, Sunovion, Supernus, Takeda and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck and Pfizer. He received grant support from Takeda.

  • Provenance and peer review Commissioned; internally peer reviewed.